AOC 1001 Earns Breakthrough Therapy Designation for Myotonic Dystrophy Type 1 (DM1)
source: shutterstock.com

AOC 1001 Earns Breakthrough Therapy Designation for Myotonic Dystrophy Type 1 (DM1)

Currently, there are no approved treatment options for myotonic dystrophy type 1 (DM1), a progressive neuromuscular disease. As the disease progresses, affected individuals experience muscle weakness, respiratory distress, and cardiac…

Continue Reading AOC 1001 Earns Breakthrough Therapy Designation for Myotonic Dystrophy Type 1 (DM1)
New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz
source: shutterstock.com

New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz

Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Murray Walz, a…

Continue Reading New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz